Literature DB >> 23001343

Therapeutics: PI3K-PARP combination.

Gemma K Alderton.   

Abstract

Year:  2012        PMID： 23001343     DOI： 10.1038/nrc3372

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN： 1474-175X            Impact factor:   60.716


× No keyword cloud information.
  2 in total

1.  Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer.

Authors:  Ashish Juvekar; Laura N Burga; Hai Hu; Elaine P Lunsford; Yasir H Ibrahim; Judith Balmañà; Anbazhagan Rajendran; Antonella Papa; Katherine Spencer; Costas A Lyssiotis; Caterina Nardella; Pier Paolo Pandolfi; José Baselga; Ralph Scully; John M Asara; Lewis C Cantley; Gerburg M Wulf
Journal:  Cancer Discov       Date:  2012-08-22       Impact factor: 39.397

2.  PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition.

Authors:  Yasir H Ibrahim; Celina García-García; Violeta Serra; Lei He; Kristine Torres-Lockhart; Aleix Prat; Pilar Anton; Patricia Cozar; Marta Guzmán; Judit Grueso; Olga Rodríguez; Maria Teresa Calvo; Claudia Aura; Orland Díez; Isabel T Rubio; José Pérez; Jordi Rodón; Javier Cortés; Leif W Ellisen; Maurizio Scaltriti; José Baselga
Journal:  Cancer Discov       Date:  2012-08-22       Impact factor: 39.397
  2 in total
  1 in total

1.  Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer--response.

Authors:  Robert J G Cardnell; Lauren A Byers
Journal:  Clin Cancer Res       Date:  2014-03-31       Impact factor: 12.531
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.